Avidity Biosciences Total Assets 2019-2021 | RNA

Avidity Biosciences total assets from 2019 to 2021. Total assets can be defined as the sum of all assets on a company's balance sheet.
Avidity Biosciences Annual Total Assets
(Millions of US $)
2020 $334
2019 $97
2018 $0
Avidity Biosciences Quarterly Total Assets
(Millions of US $)
2021-09-30 $426
2021-06-30 $291
2021-03-31 $315
2020-12-31 $334
2020-09-30 $346
2020-06-30 $355
2020-03-31 $0
2019-12-31 $0
2019-09-30 $0
2019-06-30 $0
2018-12-31 $0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.836B $0.007B
Avidity Biosciences Inc. is a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates(TM). The company's AOC platform design, engineer and develop therapeutics which combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies. Its lead product candidate consist AOC 1001, is designed to treat myotonic dystrophy type 1,and other muscle programs are focused on the treatment of muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy and Pompe disease. Avidity Biosciences Inc. is based in SAN DIEGO.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $144.122B 9.11
Bio-Rad Laboratories (BIO.B) United States $18.677B 37.90
QIAGEN (QGEN) Netherlands $11.053B 18.72
Biohaven Pharmaceutical Holding (BHVN) United States $8.002B 0.00
Emergent Biosolutions (EBS) United States $2.809B 10.10
Arcus Biosciences (RCUS) United States $2.516B 0.00
Myovant Sciences (MYOV) United Kingdom $1.432B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.186B 0.00
Zymeworks (ZYME) Canada $0.697B 0.00
Ambrx Biopharma (AMAM) United States $0.230B 0.00
SQZ Biotechnologies (SQZ) United States $0.229B 0.00
Enzo Biochem (ENZ) United States $0.160B 20.69